Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Erratum (v22,p969)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Skotheim, R. I.
Right arrow Articles by Lothe, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Skotheim, R. I.
Right arrow Articles by Lothe, R. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 21, Issue 24 (December), 2003: 4586-4591
© 2003 American Society for Clinical Oncology

Topoisomerase-II{alpha} Is Upregulated in Malignant Peripheral Nerve Sheath Tumors and Associated With Clinical Outcome

Rolf I. Skotheim, Anne Kallioniemi, Bodil Bjerkhagen, Fredrik Mertens, Helge R. Brekke, Outi Monni, Spyro Mousses, Nils Mandahl, Gunnar Soeter, Jahn M. Nesland, Sigbjørn Smeland, Olli-P. Kallioniemi, Ragnhild A. Lothe

From the Departments of Genetics and Pathology, Institute for Cancer Research, and the Department of Oncology, the Norwegian Radium Hospital and University of Oslo, Oslo, Norway; the Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere; Biomedicum Biochip Center, Biomedicum Helsinki, Helsinki; and VTT Technical Research Centre of Finland and University of Turku, Turku, Finland; Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD; and the Department of Clinical Genetics, University Hospital, Lund, Sweden.

Address reprint requests to Ragnhild A. Lothe, PhD, Department of Genetics, Institute for Cancer Research, the Norwegian Radium Hospital, N-0310 Oslo, Norway; e-mail: rlothe{at}radium.uio.no.

Purpose: To identify target genes of clinical significance for patients with malignant peripheral-nerve sheath tumor (MPNST), an aggressive cancer for which no consensus therapy exists.

Materials and Methods: Biopsies and clinical data from 51 patients with MPNST were included in this study. Based on our previous research implicating chromosome arm 17q amplification in MPNST, we performed gene expression analyses of 14 MPNSTs using chromosome 17–specific cDNA microarrays. Copy numbers of selected gene probes and centromere probes were then determined by interphase fluorescence in situ hybridization in 16 MPNSTs. Finally, we generated a tissue microarray containing 79 samples from 44 MPNSTs, on which in situ protein expressions of candidate genes were examined and related to clinical end points.

Results: Among several deregulated genes found by cDNA microarray analyses, topoisomerase II{alpha} (TOP2A) was the most overexpressed gene in MPNSTs compared with benign neurofibromas. Excess copies of the TOP2A were also seen at the DNA level in 10 of 16 cases, and high expression of the TOP2A protein was seen in 83% of the tumors on the tissue microarray. The TOP2A-expressing tumors were associated with poor cancer-specific survival and presence of metastases.

Conclusion: We have identified TOP2A as a target gene in MPNST, using a focused gene expression profiling followed by a DNA copy number evaluation and clinical validation of the encoded protein using a tissue microarray. This study is the first to suggest that TOP2A expression may be a predictive factor for adverse outcome in MPNST.

Supported by the Research Council of Norway (R.I.S.) and the Norwegian Cancer Society (R.I.S. and R.A.L.).


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Neuro Oncol DukeHome page
H. R. Brekke, M. Kolberg, R. I. Skotheim, K. S. Hall, B. Bjerkehagen, B. Risberg, H. A. Domanski, N. Mandahl, K. Liestol, S. Smeland, et al.
Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors
Neuro-oncol, January 1, 2009; 11(5): 514 - 528.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. Bhojwani, H. Kang, N. P. Moskowitz, D.-J. Min, H. Lee, J. W. Potter, G. Davidson, C. L. Willman, M. J. Borowitz, I. Belitskaya-Levy, et al.
Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study
Blood, July 15, 2006; 108(2): 711 - 717.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
D. Van Hoof, R. Passier, D. Ward-Van Oostwaard, M. W. H. Pinkse, A. J. R. Heck, C. L. Mummery, and J. Krijgsveld
A Quest for Human and Mouse Embryonic Stem Cell-specific Proteins
Mol. Cell. Proteomics, July 1, 2006; 5(7): 1261 - 1273.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
K Karube, K Nabeshima, M Ishiguro, M Harada, and H Iwasaki
cDNA microarray analysis of cancer associated gene expression profiles in malignant peripheral nerve sheath tumours
J. Clin. Pathol., February 1, 2006; 59(2): 160 - 165.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2003 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online